MarketVIEW: Quadrivalent influenza vaccines (CAT No: VAMV036)

Annual seasonal influenza epidemics typically affect 5-15% of the population with mainly upper respiratory tract infections. On a global basis around 3-5 million cases of severe illness are estimated each year with an associated 250,000 - 500,000 deaths (WHO figures). Annual influenza vaccination is the most effective method for preventing influenza virus infection and its complications. Recommended groups for influenza vaccination are usually those most vulnerable and include the elderly, very young and those with underlying chronic diseases. In the US, influenza vaccination recommendations now include every person >6 mos. Influenza vaccines are predominantly of the trivalent inactivated format (TIV) although latest advances include the addition of another B virus strain to form quadrivalent (QIV) vaccines.

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of Quadrivalent influenza (QIV) vaccines across major Western and 20 emerging markets to 2030. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, pricing and penetration estimates. 3 possible uptake scenarios for QIVs are included based upon the level of populations targeted. Estimated potential revenues for the main competitors are also included along with a review of their development status to date.

Please note: this is delivered as a Zip file.